Roche announced acquisition of Anadys for $3.70/share cash (~$230M), a 256% premium. Strategic HCV consolidation aimed at all-oral interferon-free regimens; competitive response to Gilead/Pharmasset and BMS/Inhibitex.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Dilutive
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
AnnouncedOct 17, 2011
ClosedDec 01, 2011
Deal value$230M
Deal typeAcquisition/Merger
Therapeutic areaChronic hepatitis C virus infection